# Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma

> **NCT00022555** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- AIDS-related Diffuse Large Cell Lymphoma
- AIDS-related Diffuse Mixed Cell Lymphoma
- AIDS-related Peripheral/Systemic Lymphoma
- AIDS-related Small Noncleaved Cell Lymphoma

## Interventions

- **DRUG:** bryostatin 1
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00022555
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2003-07
- **Final completion:** —
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2013-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022555, "Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00022555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*